Skip to main content
STAR Protocols logoLink to STAR Protocols
. 2022 May 13;3(2):101386. doi: 10.1016/j.xpro.2022.101386

Protocol to generate xenogeneic-free/serum-free human dental pulp stem cells

Soichiro Sonoda 1,5,6,, Haruyoshi Yamaza 2,5, Koichiro Yoshimaru 3, Tomoaki Taguchi 3,4, Takayoshi Yamaza 1,7,∗∗
PMCID: PMC9112100  PMID: 35592060

Summary

Human dental pulp stem cell (hDPSCs)-based therapy is a feasible option for regenerative medicine, such as dental pulp regeneration. Here, we show the steps needed to colony-forming unit-fibroblasts (CFU-F)-based isolation, expansion, and cryopreservation of hDPSCs for manufacturing clinical-grade products under a xenogeneic-free/serum-free condition. We also demonstrate the characterization of hDPSCs by CFU-F, flow cytometric, and in vitro multipotent assays.

For complete details on the use and execution of this protocol, please refer to Iwanaka et al. (2020).

Subject areas: Cell isolation, Clinical Protocol, Stem Cells

Graphical abstract

graphic file with name fx1.jpg

Highlights

  • Protocol to generate xenogeneic-free/serum-free hDPSCs

  • Expansion, cryopreservation, and recovery for biobanking of hDPSCs

  • CFU-F, flow cytometric, and in vitro multipotent assays for characterization of hDPSCs


Human dental pulp stem cell (hDPSCs)-based therapy is a feasible option for regenerative medicine, such as dental pulp regeneration. Here, we show the steps needed to colony-forming unit-fibroblasts (CFU-F)-based isolation, expansion, and cryopreservation of hDPSCs for manufacturing clinical-grade products under a xenogeneic-free/serum-free condition. We also demonstrate the characterization of hDPSCs by CFU-F, flow cytometric, and in vitro multipotent assays.

Before you begin

Human dental pulp stem cells (hDPSCs) were identified in dental pulp tissue of deciduous and permanent teeth (Gronthos et al., 2000; Miura et al., 2003) and apical papillae of developing teeth (Sonoyama et al., 2006). hDPSCs exhibit remarkable mesenchymal stem cell (MSC) characteristics, including self-renewal, immunophenotype, and multipotency into osteoblasts, adipocytes, and chondrocytes (Yamaza et al., 2010). We have focused on the stem cell potency of hDPSCs for regenerative medicine; Immunosuppressive function of hDPSCs can be an option for treating systemic lupus erythematosus (SLE) (Ma et al., 2012, 2015; Makino et al., 2013). Transdifferentiation capacities into hepatocytes and cholangiocytes and cell aggregation ability of hDPSCs is applicable in liver and bone regeneration (Yamaza et al., 2015; Tanaka et al., 2018, 2019; Fujiyoshi et al., 2019; Takahashi et al., 2019; Yuniartha et al., 2021). Extracellular vesicles of hDPSCs improve bone density and immune tolerance in osteoporosis and SLE, respectively (Sonoda et al., 2020, 2021a). Pulpitis- and biliary atresia-specific hDPSCs are suggested as a potent autologous option for dental pulp and liver regeneration (Sonoda et al., 2016, 2018; 2021b). Bilirubin-free and pamidronate treatment could rejuvenate deficient hDPSCs under an experimental biliary atresia condition (Yamaza et al., 2018a; 2018b). Thus, hDPSCs-based therapy is considered to be a novel option for regenerative medicine (Sonoda et al., 2015; Taguchi et al., 2019). The employment of fetal bovine serum (FBS) in cell manufacturing faces severe immunological concerns in clinical application (Karnieli et al., 2017). Recently, we have established a protocol for producing clinical graded hDPSCs under a xenogeneic-free/serum-free condition by colony-forming unit-fibroblasts (CFU-F) method (Friedenstein et al., 1974) and provided feasible hDPSC products to treat chronic liver fibrosis in an animal model. (Iwanaka et al., 2020).

Institutional permissions

Ethical approvals and institutional permissions are required for the use of human samples. Procedures for handling dental pulp tissues from human deciduous teeth referred in this protocol were approved by the Kyushu University Institutional Review Board for Human Genome/Gene Research (protocol numbers: 738-01, 02, 03, and 04). All experiments conform to the relevant regulatory standards.

Key resources table

REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies

R-PE mouse anti-human CD11b IgG1 [HI111] (used at 1 μg/mL) BioLegend Cat # 301207
R-PE mouse anti-human CD14 IgG1 [63D3] (used at 1 μg/mL) BioLegend Cat # 367103
R-PE mouse anti-human CD34 IgG2a [561] (used at 1 μg/mL) BioLegend Cat # 343605
R-PE mouse anti-human CD45 IgG1 [2D1] (used at 1 μg/mL) BioLegend Cat # 368509
R-PE mouse anti-human CD73 IgG1 [AD2] (used at 1 μg/mL) BioLegend Cat # 344003
R-PE mouse anti-human CD90 IgG1 [5E10] (used at 1 μg/mL) BioLegend Cat # 328109
R-PE mouse anti-human CD105 IgG1 [43A3] (used at 1 μg/mL) BioLegend Cat # 323205
R-PE mouse anti-human CD146 IgG1 [P1H12] (used at 1 μg/mL) BioLegend Cat # 361006
R-PE mouse anti-human HLA-DR IgG2a [L243] (used at 1 μg/mL) BioLegend Cat # 307605
R-PE mouse IgG1 kappa [MOPC-21] (used at 1 μg/mL) BioLegend Cat # 400113
R-PE mouse IgG2a kappa [MOPC-173] (used at 1 μg/mL) BioLegend Cat # 400213

Chemicals, peptides, and recombinant proteins

7-AAD viability staining solution BioLegend Cat # 42043
Acetic Acid Nacalai Tesque Cat # 00212-85
Alcian blue 8GX Merck Cat # A5268
Alizarin red S Merck Cat # A5533
L-Ascorbic Acid 2-Phosphate FUJIFILM Wako Chemicals Cat # 323-44822
Dexamethasone Merck Cat # D4902-1G
Dulbecco’s Minimum Essential Medium (DMEM), Low Glucose (1.0 g/L) Nacalai Tesque Cat # 08456-65
Dulbecco’s Phosphate Buffered Saline (D-PBS) (1×) Nacalai Tesque Cat # 14249-95
D-PBS (10×) Nacalai Tesque Cat # 11482-15
EagleTaq Master Mix Roche Cat # 5876486001
Ethanol, Absolute Nacalai Tesque Cat# 08948-45
Fetal bovine serum (FBS) [170629-0130] Equitech Bio Cat # SFBM30-0500
Hydrocortisone Merck Cat # 386698-25MGCN
Hanks’ balanced salt solution (HBSS) (1×) Nacalai Tesque Cat# 09735-75
Indomethacin Merck Cat # 405268-10GMCN
3-Isobutyl-1-methylxanthine (IBMX) Merck Cat # 410957-1GMCN
Isopropanol Nacalai Tesque Cat # 29113-95
ITSTM Premix BD Bioscience-Discovery Labware Cat # 354351
LiberaseTM MNP-S Roche Custom Biotech Cat # 05578566001
Liquid nitrogen N/A N/A
Marinol750cpc Muto Pure Chemicals Cat # 20091
MSC NutriStem® XF Basal Medium Biological Industry Cat # 05-200-1A
MSC NutriStem® XF Supplement Mix Biological Industry Cat # 05-201-1U
Oil red O Merck Cat # O0625
Paraffin, Paraplast plus® for tissue embedding Leica Biosystems Cat # 39601095
Paraformaldehyde (PFA) Merck Cat # 818715
Penicillin-Streptomycin-Amphotericin B Mixed Solution (100×) Nacalai Tesque Cat # 02892-54
Potassium Dihydrogen Phosphate FUJIFILM Wako Chemicals Cat # 163-04243
ReverTraAce® qPCR RT Master Mix TOYOBO Cat # FSQ-201
RNeasy Mini Kit QIAGEN Cat # 74104
RQ1 RNase-free DNase Promega Cat # M6101
STEM CELL BANKER® cryomedium Zenoak Cat # CB061
Sodium Hydroxide solution (1 N) Nacalai Tesque Cat # 37421-05
Sodium Pyruvate solution (5 mM) Nacalai Tesque Cat # 06977-34
Toluidine blue Merck Cat # T3260
Transforming Growth Factor beta 1 (TGFB1) PeproTech Cat # AF-100-21C-10ug
Trypan blue solution Bio-Rad Laboratories Cat # 1450021
TRIzol® reagent Thermo Fisher Scientific Cat # 15596026
TrypLETM select without phenol red Thermo Fisher Scientific Cat # 12563011
Turk’s solution Merck Cat # 1.09277
Xylene Nacalai Tesque Cat # 36612-35

Biological samples

Human teeth N/A N/A

Oligonucleotides

BGLAP [Hs01587814_g1] Thermo Fisher Scientific Cat # 4331182
COL10A1 [S00166657_m1] Thermo Fisher Scientific Cat # 4331182
LPL [Hs00173425_m1] Thermo Fisher Scientific Cat # 4331182
PPARG [Hs0115513_m1] Thermo Fisher Scientific Cat # 4331182
rRNA, 18S [Hs99999901_s1] Thermo Fisher Scientific Cat # 4331182
RUNX2 [Hs00231692_m1] Thermo Fisher Scientific Cat # 4331182
SOX9 [Hs01001343_g1] Thermo Fisher Scientific Cat # 4331182

Other

Automated cell counter, TC20TM Bio-Rad Laboratories Cat # 1450101J1
Cell counting slide for TC10 TM /TC20TM Bio-Rad Laboratories Cat # 1450011
Cell culture dish, 35 mm Corning, Falcon® Cat # 354467
Cell culture dish, 60 mm Corning, Falcon® Cat # 353002
Cell culture dish, 100 mm Corning, Falcon® Cat # 353003
Cell culture e flask, T-75 Corning, Falcon® Cat # 353135
Cell culture plate, 6-well Corning, Falcon® Cat # 353046
Cell culture plate, 96-well, round bottom, PrimeSurface® Sumitomo Bakelite Cat # MS-9096U
Cell scraper Corning, Falcon® Cat # 353089
Cell strainer, 70 μm Corning, Falcon® Cat # 352350
Cell thawing system, ThawSTAR® CFT2 Biolife Solutions Cat # AST-601
Centrifuge machine N/A N/A
Centrifuge Tube, conical, polypropylene, 1.5 mL Nichiryo Cat # 00-ETS-CT-15
Centrifuge Tube, conical, polypropylene, 15 mL Corning, Falcon® Cat # 352096
Centrifuge Tube, conical, polypropylene, 50 mL Corning, Falcon® Cat # 352070
Centrifuge Tube, round bottom, polypropylene, 5 mL Corning, Falcon® Cat # 352008
CO2 incubator N/A N/A
Cryogenic vial Sumitomo Bakelite Cat # MS-4501G
Dissecting instruments (dental disk, dental probe, endodontic file, forceps, scalpel, surgical blade #23) N/A N/A
Flow cytometric (FCM) analyzer N/A N/A
Filter, disc, 0.2 μm Advantech Cat # 25CS020AS
Filter, membrane, 0.2 μm Advantech Cat # C020A047A
Filter, paper, No. 3, 150 mm Advantech Cat # 01301150
Filter, paper, No. 5B, 150 mm Advantech Cat # 01521150
Flask, T-75 Corning, Falcon® Cat # 353136
Freezing container N/A N/A
Light microscopy, inverted N/A N/A
Light microscopy, upright N/A N/A
Liquid nitrogen tank N/A N/A
PCR plate, 96-well N/A N/A
Petri dish, 100 mm Corning, Falcon® Cat # 351029
Realtime-PCR machine N/A N/A
Stereoscopic microscopy N/A N/A
Vortex mixer N/A N/A
Water bath N/A N/A

Materials and equipment

Sample transfer medium

Reagent Final concentration Amount
DMEM, Low Glucose (1.0 g/L) n/a 49.5 mL
Penicillin-Streptomycin-Amphotericin B Mixed Solution (100×) 100 units/mL / 100 μg/mL / 0.25 μg/mL 0.5 mL
Total n/a 50 mL

Store at 4°C until for up to 1 month.

Note: Sample transfer medium is used for maintaining tissue/cell activity during sample transfer. Store each 10 mL of sample transfer medium at 4°C in a 50 mL conical polypropylene centrifuge tube before used.

Tissue digestion medium

Reagent Final concentration Amount
LiberaseTM MNP-S 0.45 units/mL up to product lot
D-PBS (1×) n/a 6 mL
Total n/a 6 mL

Prepare fresh and keep at 4°C until used and prewarm at 37°C before used.

Note: Tissue digestion medium should be prepared just before isolation.

Complete growth medium (CGM)

Reagent Final concentration Amount
MSC NutriStem® XF Basal Medium n/a 500 mL
MSC NutriStem® XF Supplement Mix n/a 3 mL
Total n/a 503 mL

Store at 4°C until for up to 1 month and prewarm at 37°C before used.

PFA solution

Reagent Final concentration Amount
PFA 4% 20.0 g
D-PBS (10×) n/a 50 mL
Milli-Q water n/a 480 mL
Total 4% 500 mL

Store at 4°C until for up to 1 month.

Note: The following protocol may be helpful for preparing 4% PFA solution.

  • Warm 400 mL of Milli-Q water at 60°C.

  • Add 20 g of PFA powder and mix well.

  • Add 1 mL of 1 N NaOH and mix well.

  • Add 50 mL of 10 × D-PBS, mix well, and iced for 30 min.

  • Filter using a No. 3 paper filter.

  • Adjust to pH 7.2–7.4 and fill up to 50 mL.

Toluidine blue solution

Reagent Final concentration Amount
Toluidine blue 0.4% 2.0 g
Milli-Q water n/a 500 mL
Total 0.4% 500 mL

Store at 20°C until for up to 1 month.

Toluidine blue staining solution

Reagent Final concentration Amount
PFA solution (4%) 1% 50 mL
Toluidine blue solution (0.4%) 0.2% 100 mL
Milli-Q water n/a 50 mL
Total 0.4% 200 mL

Store at 20°C until for up to 1 month.

Note: Toluidine blue staining solution should be mixed and filtered using a No. 5B paper filter just before used.

FCM buffer

Reagent Final concentration Amount
HBSS (1×) n/a 49 mL
FBS, heat inactivated 2% 1 mL
Total n/a 50 mL

Store at 4°C until for up to 1 week.

Note: FCM buffer should be filtered using a 0.45 μm paper filter after mixed.

L-Ascorbic Acid 2-Phosphate solution

Reagent Final concentration Amount
L-Ascorbic Acid 2-Phosphate 100 mM 322 mg
MSC NutriStem® XF Basal Medium n/a 100 mL
Total n/a 100 mL

Store at −20°C until for up to 1 month.

Note: Store each 5 mL of L-Ascorbic Acid 2-Phosphate solution at −20°C in a 15 mL conical polypropylene centrifuge tube before used.

Potassium Dihydrogen Phosphate solution

Reagent Final concentration Amount
Potassium Dihydrogen Phosphate 180 mM 984 mg
MSC NutriStem® XF Basal Medium n/a 40 mL
Total n/a 40 mL

Store at −20°C until for up to 1 month.

Note: Store each 5 mL of Potassium Dihydrogen Phosphate solution at −20°C in a 15 mL conical polypropylene centrifuge tube before used.

Dexamethasone solution

Reagent Final concentration Amount
Dexamethasone 180 mM 1 vial
Ethanol, Absolute n/a 1 mL
MSC NutriStem® XF Basal Medium n/a 9 mL
Total n/a 10 mL

Store at −20°C until for up to 1 month.

Note: Dilute Dexamethasone with 1 mL of absolute ethanol well and add 9 mL of MSC NutriStem® XF Basal Medium. Store each 50 μL of Dexamethasone solution at −20°C in a 1.5 mL conical polypropylene centrifuge tube before used.

IBMX solution

Reagent Final concentration Amount
IBMX (50 mM) 50 mM 111 mg
Ethanol, Absolute n/a 10 mL
Total n/a 10 mL

Store at 20°C until for up to 1 month.

Note: Keep to protect from the light to avoid loss of activity.

Indomethacin solution

Reagent Final concentration Amount
Indomethacin 6 mM 215 mg
Ethanol, Absolute n/a 100 mL
Total n/a 100 mL

Store at 20°C until for up to 1 month.

Note: Keep to protect from the light to avoid loss of activity.

Hydrocortisone Phosphate solution

Reagent Final concentration Amount
Hydrocortisone (500 mM) 0.5 mM 18 mg
Ethanol, Absolute n/a 100 mL
Total n/a 100 mL

Store at 20°C until for up to 1 month.

Note: Keep to protect from the light to avoid loss of activity.

TGFB1 solution

Reagent Final concentration Amount
TGFB1 1 μg/mL 10 μg
D-PBS (1×) n/a 10 mL
Total n/a 10 mL

Store at −20°C until for up to 1 month.

Note: Store each 100 μL of TGFB1 solution at −20°C in a 1.5 mL conical polypropylene centrifuge tube before used.

Osteogenic induction solution

Reagent Final concentration Amount
MSC NutriStem® XF Basal Medium n/a 490 mL
MSC NutriStem® XF Supplement Mix n/a 3 mL
L-Ascorbic Acid 2-Phosphate solution (10 mM) 100 μM 5 mL
Potassium Dihydrogen Phosphate solution (180 mM) 2 mM 5 mL
Dexamethasone solution (100 mM) 10 nM 50 μL
Total n/a 500 mL

Store at 4°C until for up to 1 month.

Adipogenic induction solution

Reagent Final concentration Amount
MSC NutriStem® XF Basal Medium n/a 481.5 mL
MSC NutriStem® XF Supplement Mix n/a 3 mL
L-Ascorbic Acid 2-Phosphate solution (10 mM) 100 μM 5 mL
IBMX solution (180 mM) 500 μM 5 mL
Indomethacin solution (6 mM) 60 μM 5 mL
Hydrocortisone solution (500 mM) 500 nM 500 μL
Total n/a 500 mL

Store at 4°C until for up to 1 month.

Chondrogenic induction solution

Reagent Final concentration Amount
MSC NutriStem® XF Basal Medium n/a 9.44 mL
MSC NutriStem® XF Supplement Mix n/a 60 μL
L-Ascorbic Acid 2-Phosphate solution (10 mM) 100 μM 100 μL
ITSTM Premix n/a 100 μL
Dexamethasone solution (100 mM) 100 nM 0.05 μL
Sodium Pyruvate solution (5 mM) 100 μM 200 μL
TGFB1 solution (1 μg/mL) 10 ng/mL 100 μL
Total n/a 10 mL

Store at 4°C until for up to 1 month.

Alizarin red S staining solution

Reagent Final concentration Amount
Alizarin red S 1% 2.5 g
Milli-Q water n/a 250 mL
Total n/a 250 mL

Store at 20°C until for up to 1 month.

Note: Filter using a No. 3 paper filter before used.

Oil red O staining stock solution

Reagent Final concentration Amount
Oil red O 0.5% 0.5 g
Isopropanol n/a 100 mL
Total n/a 100 mL

Store at −20°C until for up to 1 month.

Note: Filter using a No. 3 paper filter before used.

Oil red O staining working solution

Reagent Final concentration Amount
Oil red O staining stock solution 0.3% 15 mL
Milli-Q water n/a 10 mL
Total n/a 25 mL

Store at −20°C until for up to 1 month.

Note: Filter using a No. 3 paper filter before used.

Alcian blue staining solution

Reagent Final concentration Amount
Alcian blue 8GX 1% 1 g
Acetic Acid (3%) n/a 100 mL
Total n/a 25 mL

Store at −20°C until for up to 1 month.

Note: Adjust pH to 2.5 using acetic acid. Filter using a No. 3 paper filter before used.

Step-by-step method details

Sample collection and transfer

Inline graphicTiming: depending on the process in your institution and number of tooth samples

This section describes the transfer condition of collected human samples.

  • 1.
    Sample transfer.
    • a.
      Extract human tooth samples under a general surgical condition and put them into sample transfer medium in a 5 mL conical polypropylene centrifuge tube (Figure 1).
      Note: Human tooth samples derived from any donors with age and gender are available for generating hDPSCs.
    • b.
      Transport the samples at 4°C within 24 h and maintain the samples at 4°C before used.

Figure 1.

Figure 1

Storing of a tooth sample

An imaged of a deciduous tooth sample stored in a polypropylene vial containing sample transfer medium at 4°C.

Cell preparation and seeding

Inline graphicTiming: 1–2 h, depending on the number of tooth samples

This section describes the procedure to isolate all nucleated cells (ANCs) from human dental pulp tissue.

  • 2.
    Tissue preparation and digestion.
    • a.
      Tissue preparation.
      • i.
        Discard the transfer medium and wash the samples with 10 mL of D-PBS 3 times (Figures 2A and 2B).
      • ii.
        Hold the sample using a forceps. Pull-out dental pulp tissue using an endodontic file or dental probe under a stereoscopic microscopy on a 100 mm petri dish (Figure 2C).
        Optional: If it is not easy to pull out dental pulp tissue directly, cut the tooth along cementoenamel junction using a dental disk and separate into the crown and root parts (see troubleshooting, problem 1).
      • iii.
        Drop 100–200 μL of D-PBS on the sample (Figure 2D).
      • iv.
        Mince the tissue sample in a pulp by using a scalpel with surgical blade #23.
        Inline graphicCRITICAL: This step is critical to obtain larger number of dental pulp cells. The tissue should be minced as minute as possible to be in a pulp (Figure 2E).
    • b.
      Tissue digestion.
      • i.
        Immerse the pulp tissue sample into 6 mL of tissue digestion medium in a 50 mL conical polypropylene centrifuge tube (Figure 3A).
      • ii.
        Incubate the medium for 30 min at 37°C in a water bath. Mix every 10 min with a Vortex mixer to help break up tissue (Figure 3B).
      • iii.
        Centrifuge at 300 × g at 4°C for 6 min. Aspirate the supernatant carefully. Resuspend the cell pellet gently with 1 mL of CGM and add 4 mL of CGM. Repeat this step again.
      • iv.
        Pass the cell suspension through a 70 μm cell strainer.
      • v.
        Centrifuge at 300 × g at 4°C for 6 min and aspirate the supernatant carefully. Resuspend the cell pellet gently with 1 mL of CGM and store at 4°C.
  • 3.
    Cell counting.
    • a.
      To stain ANCs, mix10 μ L of cell suspension with 90 μ L of Turk’s solution in a 1.5 mL polystyrene conical centrifuge tube.
      Optional: Living cells may be visualized by 0.4% trypan blue cell staining solution.
    • b.
      Count number of ANCs in triplicate with a TC20TM automated cell counter using a cell counting slide for TC10 TM /TC20TM. Determine cell number from the mean of the three measurements.
      Note: ANCs are usually obtained 1–5 × 106 cells of ANCs can be obtained from one tooth.

Figure 2.

Figure 2

Preparation of tooth sample

(A) An image of a tooth sample washed in 1 mL of Dulbecco’s phosphate buffered saline (D-PBS) on a petri dish.

(B) An image of the cleaned tooth sample after washing on the petri dish.

(C) An image of a dental pulp tissue (arrow) pulled from the tooth sample by using an endodontic file.

(D) An image of the pulled dental pulp tissue kept in a droplet of 100 μL of D-PBS on the petri dish.

(E) An image of the dental pulp tissue after minced in the droplet of D-PBS on the petri dish.

Figure 3.

Figure 3

Digesting of dental pulp tissue

(A) An image of the minced dental pulp tissue in 6 mL of tissue digestion medium before digestion.

(B) An image of the dental pulp tissue after digestion for 30 min at 37°C. Arow: digested tissue debris.

CFU-F forming isolation

Inline graphicTiming: 10–14 days, depending on colony forming condition

This section describes the procedure for forming CFU-F from ANCs. This part is most critical section throughout this procedure.

  • 4.
    Colony forming culture (Figure 4).
    • a.
      Seed ANCs at 1–2 × 106 cells in 10 mL of CGM onto T-75 flask. Shake the flasks gently on 8-loop.
    • b.
      Incubate the flasks for 18 h at 37°C with 5% CO2 in a CO2 incubator.
    • c.
      Wash the flasks gently with 3 mL of D-PBS 3 times to eliminate unattached cells. Add 10 mL of CGM and maintain the flasks at 37°C with 5% CO2 in a CO2 incubator.
      Note: Plastic adherence is one of important characteristics of MSCs.
      Note: The flasks should be left without any handling during initial 3 days to avoid the mechanical detachment of weak-attached cells.
    • d.
      Replace with 10 mL of CGM 7 days after seeding and maintain further 7 days.
      Note: Adherent cell colony formation should be recognized under an inverted light microscopy approximately 10–14 days after seeding (see troubleshooting, problem 2).
      Note: Culture period may be different to each sample. Observe the density of the formed adherent colonies carefully under microscopy. When some colonies reach high density, cell dissociation is available for cell expansion.

Figure 4.

Figure 4

Forming of single attached cell-derived adherent colony

(A) A microscopic image of a single attached cell (arrow) on a culture flask.

(B) A microscopic image of the cell division of single attached cells on the culture flask.

(C) A microscopic image of the immature adherent cell cluster on the culture flask 8 days after cell seeding.

(D) A microscopic image of the mature adherent cell cluster on the culture flask 14 days after cell seeding. Scale bars, 100 μm.

Cell passage and expansion

Inline graphicTiming: 7–10 days, depending on colony forming condition

This section describes the procedure for expanding CFU-F-forming cells to obtain large amount of hDPSCs.

  • 5.
    Cell dissociation.
    • a.
      Gently wash the flask twice with 3 mL of D-PBS.
    • b.
      Put 1 mL of cell dissociation reagent, TrypLETM select without phenol red, into each flask and incubate for 5 min at 37°C with 5% CO2 in a CO2 incubator.
    • c.
      Add 2 mL of CGM per flask and suspend gently well to remove colony-forming cells from flask. Transfer the cell suspension into a 50 mL conical polypropylene centrifuge tube through a 70-μm cell strainer and centrifuge at 300 × g at 4°C for 6 min on a centrifuge machine.
    • d.
      Discard the supernatant and resuspend the cell pellet with 1 mL of CGM gently. Count the number of ANCs as described in step 3.
  • 6.
    Cell expansion.
    • a.
      Seed 1.0–2.5 × 105 cells per flask into 10 mL of CGM onto T 75 flask and maintain hDPSCs in 10 mL of CGM at 37°C with 5% CO2 in a CO2 incubator.
    • b.
      Change CGM twice a week.
    • c.
      Passage or cryopreserve hDPSCs when reached at 70% confluent condition.

Cell cryopreservation

Inline graphicTiming: 6 h, depending on colony forming condition

This section describes the procedure for cryopreservation of expanded hDPSCs.

  • 7.
    Cell cryopreservation.
    • a.
      Dissociate cultured cells as described in step 5. Resuspend cell pellet 1 mL of STEM CELL BANKER® cryomedium instead of CGM and store at 4°C. Count the number of ANCs as described in step 3.
    • b.
      Adjust the concentration to 2.0 × 106/mL with additional cryomedium and divide 1 mL of the cell suspension per cryogenic vial.
    • c.
      Keep the vials for 4 h at −80°C in a cell freezing container, then store in liquid nitrogen.

Cell thawing

Inline graphicTiming: ∼30 min, depending on colony forming condition

This section describes the procedure for thawing of cryopreserved hDPSCs for further expansion.

  • 8.
    Cell thawing.
    • a.
      Put a cryogenic vial in a cell thawing system, ThawSTAR® CFT2, and transfer thawed cells into a 15 mL polystyrene conical centrifuge tube with 4 mL of CGM.
      Optional: Cell thawing is done using a water bath at 37°C.
    • b.
      Centrifuge at 300 × g at 4°C for 6 min and wash the thawed cells with 5 mL of CGM.
    • c.
      Aspirate the supernatant completely and suspend the cell pellet with 1 mL of CGM gently. Count the number of cells as described in step 3.
    • d.
      Seed the cells as described in step 6.

Colony forming efficiency

Inline graphicTiming: 10–14 days, depending on colony forming condition

This section describes the colony forming ability of hDPSCs by CFU-F method (Figure 5).

  • 9.
    Colony forming culture.
    • a.
      Cultured ANCs on 100 mm culture dishes as described in step 4.
      Note: Adherent cell colony formation should be recognized under an inverted light microscopy approximately 10–14 days after seeding.
      Note: Culture period may be different to each sample. Observe the density of the formed adherent colonies carefully under microscopy. When some colonies reach high density, cell staining is available. It may be better to check the colony density under an inverted light microscopy every day after day 10.
    • b.
      Wash twice with 1 mL of D-PBS and treat with toluidine blue staining solution for 1 day at 20°C.
    • c.
      Wash the dishes several times with Milli-Q water gently and dry at 20°C.
    • d.
      Capture the colonies using a light microscope and/or a scanner. Number of cell clusters, which contain larger than 50 cells, are scored under an inverted light microscope and calculate the colony-forming efficacy.

Figure 5.

Figure 5

Formation of colony-forming unit-fibroblasts (CFU-F)

(A) A scanning image of CFU-F formation on a culture flask 14 days after cell seeding by Toluidine blue staining.

(B) A microscopic image of one of small-sized CFU-Fs on the culture flask.

(C) A microscopic image of one of large-sized CFU-Fs on the culture flask. B, C: Scale bars, 100 μm.

Immunophenotype assay by flow cytometric (FCM) analysis

Inline graphicTiming: 2–3 h, depending on culture dishes

This section describes the immunophenotypical characterization of hDPSCs by FCM method (Figure 6).

  • 10.
    Immunostaining for FCM analysis.
    • a.
      Dissociate cultured hDPSCs as described in step 5, wash with HBSS, and resuspend cell pellets in 1 mL of FCM buffer.
    • b.
      Adjust the concentration of cell suspension to 1.0 × 106 ANCs/mL with additional FCM buffer, resuspend gently well, and iced, at least for 15 min.
    • c.
      Divide the cell suspension into 100 μL into a 5 mL round bottom polypropylene centrifuge tubes and keep on ice.
    • d.
      Incubate with appropriate primary antibody to CD146, CD105, CD90, CD73, CD45, CD35, CD14, CD11b, and human leukocyte antigen DR (HLA-DR) or isotype-matched controls antibody at a concentration of 1.0 μg/mL for 45 min on ice. Tap or shake the centrifuge tubes gently every 10 min.
    • e.
      Centrifuge at 300 × g at 4°C for 6 min. Wash the cells twice with 2 mL of FCM buffer as described above.
    • f.
      Put 500 μL of FCM buffer into the centrifuge tube, tap gently, and keep on ice.
    • g.
      Add 5 μL of 7-AAD viability staining solution, tap gently, and incubate for 5 min on ice in the dark.
    • h.
      Analyze the cells on a FCM analyzer. The percentage of positive living cells was determined compared to control living cells stained with corresponding isotype-matched antibodies in which a false-positive rate of less than 1% was accepted.

Note: Keep the staining tubes under shield during the staining and storing to protect from the light to avoid loss of fluorescence.

Figure 6.

Figure 6

Immunophenotype of human dental pulp stem cells (hDPSCs)

Representative histograms of cell surface antigens were analyzed by flow cytometric analysis. The numbers indicate the mean ± standard error of mean of a positive rate of target markers. Areas filled with red; target antibody-stained histograms; solid lines; isotype-matched control-stained histograms. HLA-DR, human leukocyte antigen DR; R-PE, R-phycoerythrin.

Mesenchymal multipotent assay

Inline graphicTiming: 4–6 weeks

This section describes the in vitro multipotent capabilities of hDPSCs into osteoblasts, adipocytes, and chondrocytes.

  • 11.
    Culture and staining for assessment of odontogenic/osteogenic and adipogenic potential.
    • a.
      Seed expanded hDPSCs into a 60 mm or 35 mm culture dish at 1.0 × 105 or 3 × 104 in 5 or 5 mL of CGM, respectively. Incubate the cells at 37°C with 5% CO2 in a CO2 incubator and change the medium twice a week until the cells reach to 100% confluent condition.
      Optional: Seed expanded hDPSCs into a 100 mm culture dish or a well of 6 well plate at 1.0 × 106 or 1 × 104 in 10 or 1 mL of CGM, respectively.
    • b.
      Replace the medium to an equivalent volume of osteogenic or adipogenic inductive medium. Change odontogenic/osteogenic or adipogenic inductive medium twice a week.
    • c.
      Calcium deposition is analyzed by Alizarin red S staining 4 weeks after osteogenic induction.
      • i.
        Aspirate the medium and rinse gently the cultures twice with D-PBS.
      • ii.
        Dehydrate with 1 mL of 60% isopropanol for 1 min and rehydrate in Milli-Q water for 2–3 min.
      • iii.
        Stain the cultures with 1% w/v Alizarin red S staining solution for 3–5 min at 20°C.
      • iv.
        Rinse with Milli-Q water and remove excess Alizarin red S stain dye. Air dry well.
      • v.
        Observe the cultures under an inverted light microscopy (see troubleshooting, problem 3).
    • d.
      Lipid accumulation is analyzed by Oil red O staining 4 weeks after adipogenic induction.
      • i.
        Aspirate the medium and rinse gently the cultures twice with D-PBS and fix with 4% PFA for 20 min at 20°C. Rinse with D-PBS.
      • ii.
        Hydrate with 1 mL of 60% isopropanol for 1 min.
      • iii.
        Aspirate isopropanol solution and stain the cultures with Oil Red O staining solution for 10–20 min at 20°C.
      • iv.
        Rinse the cultures with 1 mL of 60% isopropanol and remove excess Oil Red O stain dye. Store the cultures with Milli-Q water at 4°C.
      • v.
        Observe the cultures under an inverted light microscopy (see troubleshooting, problem 4).
        Note: Do not allow to air dry after Oil red O staining.
  • 12.
    Culture and staining for assessment of chondrogenic potential.
    • a.
      Seed expanded hDPSCs into a well of PrimeSurface® 96-well plate at 1.0 × 105 in 200 μL of CGM. Incubate the cells at 37°C with 5% CO2 in a CO2 incubator and change the medium gently twice a week for 1 week.
      Note: Cell spheres should be recognized under a light microscopy 1, 2, 3 days after seeding.
      Note: Medium should be changed very carefully after seeding (see troubleshooting, problem 5).
    • b.
      Replace the medium to an equivalent volume of chondrogenic inductive medium. Change the chondrogenic inductive medium gently twice a week.
    • c.
      Cartilage matrix formation is analyzed by Alcian blue staining 4 weeks after chondrogenic induction.
      • i.
        Aspirate the medium and rinse gently the cultures twice with D-PBS and fix with 4% PFA for 60 min at 20°C. Rinse with D-PBS.
        Pause point: The PFA-fixed samples can be stored at 4°C upto 1 month before paraffin embedding.
      • ii.
        Dehydrate the samples through an ascending alcohol gradient in 70% (3 min) 80% (3 min), 90% (3 min), and 100% (3 min at 3 times) alcohol and clean with xylene (3 min at 3 times). Immerse them for 8 h in melted paraffin. Embed the samples in paraffin. Cut the embedded materials into 4-μm sections.
        Pause point: The paraffin-embedded samples can be stored at 4°C or −20°C before sectioning.
      • iii.
        Dewax the paraffin sections with xylene (3 min at 3 times), rehydrate the samples through a descending alcohol gradient in 100% (3 min at 3 times), 90% (3 min), 80% (3 min), and 70% (3 min) alcohol, and immerse in Milli-Q water. Treated with 3% acetic acid solution for 2 min, and stained with Alcian blue staining solution for 30 min at 20°C.
      • iv.
        Wash in Milli-Q water, dehydrate through an ascending alcohol gradient in 70%, (3 min) 80% (3 min), 90% (3 min), and 100% (3 min, twice) ethanol, clean with xylene (3 min, twice), and treat with a mounting medium. Observe the sections under an upright light microscopy (see troubleshooting, problem 6).
  • 13.
    Specific gene expression analysis for odontogenic/osteogenic, adipogenic, and chondrogenic potential.
    • a.
      Odontoblasts/osteoblast-specific gene expression are analyzed 1 week after odontogenic/osteogenic induction. Adipocyte- and chondrocyte-specific gene expression are analyzed 4 weeks after adipogenic and chondrogenic induction.
    • b.
      Wash the cultured cells with 1 mL of D-PBS twice and add solution. Collect the cultured cells with TRIzol® reagent using a cell scraper and extract total RNA according to the manufacturer’s instruction (see https://tools.thermofisher.com/content/sfs/manuals/trizol_reagent.pdf).
      Pause point: The TRIzol-collected samples can be stored at −80°C before total RNA extraction.
      Pause point: The extracted total RNA can be stored at −80°C before total RNA purification.
    • c.
      Digest the DNA with RQ1 RNase-free DNase according to the manufacturer’s instruction (see https://www.promega.com/-/media/files/resources/protocols/product-information-sheets/g/rq1-rnase-free-dnase-protocol.pdf?rev=e52d482142fb48a68771a17c7dc458f4&sc_lang=en) and purify the digest sample with a RNeasy Mini Kit according to the manufacturer’s instruction (see https://www.qiagen.com/us/resources/resourcedetail?id=14e7cf6e-521a-4cf7-8cbc-bf9f6fa33e24&lang=en).
      Pause point: The purified total RNA can be stored at −80°C before RT-PCR reaction.
    • d.
      Synthesize cDNA by reverse transcription of total RNA using a ReverTraAce® qPCR RT Master Mix according to the manufacturer’s instruction (see https://www.toyobo-global.com/seihin/xr/lifescience/support/manual/QPK-101.pdf).
    • e.
      Amplify the cDNA with EagleTaq Master Mix and TaqMan probes for odontoblast/osteoblast-specific genes (runt related transcription factor 2 [RUNX2] and bone gamma-carboxyglutamate protein [BGLAP]), adipocyte-specific genes (peroxisome proliferator-activated receptor gamma [PPARG] and lipoprotein lipase [LPL]), chondrocyte-specific genes (SRY-box9 [SOX9] and collagen, type X, alpha 1 [COL10A1]), and 18S rRNA on 96-well PCR plates with a real-time PCR machine.
      PCR reaction master mix
      Reagent Amount
      DNA template 2 μL (10 ng)
      EagleTaq Master Mix 10 μL
      TaqMan probe 1 μL
      ddH2O 7 μL
      Present PCR reactions with the following format (if relevant):
      PCR cycling conditions
      Steps Temperature Time Cycles
      Pre-incubation 1 50°C 120 s 1
      Pre-incubation 2 95°C 600 s 1
      Denature 95°C 15 s 45
      Annealing/Extension 60°C 60 s
      Hold 4°C forever

Expected outcomes

Upon completion of this protocol, we generate xenogeneic-free/serum-free hDPSCs by CFU-F method. The generated hDPSCs are available to biobanking for expansion, cryopreservation, and recovery. The generated hDPSCs exhibit MSC characteristics including CFU-F formation, immunophenotype positive to CD146, CD105, CD90, and CD73 and negative to CD45, CD35, CD14, CD11b, and HLA-DR, and multipotency into osteoblasts, adipocytes, and chondrocytes.

Limitations

hDPSCs can be generated from human dental pulp tissues with this protocol. The number of CFU-F colonies and CFU-F-forming cells (passage 0 cells) obtained from one tooth sample ranges between 10 and 100 colonies and between 1 and 5 × 106 cells. Generating hDPSCs might not be a problem but this protocol contains a limitation when performed with human samples. Furthermore, there is a great variability to obtaining cell number of hDPSCs upon sampled tooth conditions (ex. dental caries, pulpitis, caries-treated, aged). When the dental pulp tissues are not minced well, this protocol might not work to obtain enough number of colonies/colony-forming cells.

Troubleshooting

Problem 1

At step 2, occasionally, we cannot visually find dental pulp in a tooth sample.

Potential solution

Check the sample condition. Deciduous teeth are sometimes treated due to the dental caries. Use another sample if you notice a caries treatment in the sample.

Problem 2

At step 4, we cannot often notice a single attached colony on a culture flask under microscopy a few days or more after cell seeding.

Potential solution

Keep the culture and maintain the above-mentioned conditions because very small numbers of single attached cells are often hard to find. Using a fibronectin-coated flask/dish for cell seeding is an alternative to enhance cell attachment.

Problem 3

At step 11, osteogenic matrix is shrunken or removed under osteogenic condition.

Potential solution

Change to bigger sized culture dish or well and osteogenic medium is changed very carefully.

Problem 4

At step 11, lipid accumulation cannot be found in cultured cells under microscopy after adipogenic induction according to the protocol.

Potential solution

Generally, hDPSCs exhibit a low adipogenic capacity. One- or two-week extension of the culture period may be effective.

Problem 5

At step 12, cell spheres cannot be formed after seeding or formed cell spheres are broken before and after chondrogenic induction.

Potential solution

The cultures should be wasted.

Problem 6

At step 12, cartilage matrix deposition cannot be observed in cultures under microscopy after chondrogenic induction according to the protocol.

Potential solution

Generally, hDPSCs exhibit a low chondrogenic capacity. One- or two-week extension of the culture period may be effective.

Resource availability

Lead contact

For further information or to request reagents, please direct requests to Dr. Takayoshi Yamaza, yamazata@dent.kyushu-u.ac.jp.

Materials availability

The materials used for this study can be created from commercially available materials, as is indicated in key resources table.

Acknowledgments

We thank all the authors of the original study (Iwanaka et al., 2020) from which this protocol was generated. This work was supported by the grants-in-aid for Early-Career Scientists (JSPS KAKENHI grant number JP19K18945 and JP21K16932 to S.S.) of Japan Society for the Promotion of Science (JSPS).

Author contributions

S.S. and T.Y. conceived this project and prepared the manuscript. S.S. and H.Y. conducted experiments. K.Y. and T.T. participated in method development.

Declaration of interests

The authors declare no competing interests.

Contributor Information

Soichiro Sonoda, Email: ilikeanimalaso@dent.kyushu-u.ac.jp.

Takayoshi Yamaza, Email: yamazata@dent.kyushu-u.ac.jp.

Data and code availability

The data sets supporting this protocol, and used in Figures, have not been deposited in a public repository but are available from the corresponding author upon request.

References

  1. Friedenstein A.J., Deriglasova U.F., Kulagina N.N., Panasuk A.F., Rudakowa S.F., Luriá E.A., Ruadkow I.A. Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method. Exp. Hematol. 1974;2:83–92. [PubMed] [Google Scholar]
  2. Fujiyoshi J.K., Yamaza H., Sonoda S., Yuniartha R., Ihara K., Nonaka K., Taguchi T., Ohga S., Yamaza T. Therapeutic potential of hepatocyte-like-cells converted from stem cells from human exfoliated deciduous teeth in fulminant Wilson's disease. Sci. Rep. 2019;9:1535. doi: 10.1038/s41598-018-38275-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Gronthos S., Mankani M., Brahim J., Robey P.G., Shi S. Postnatal human dental pulp stem cells (DPSCs) in vitro and in vivo. Proc. Natl. Acad. Sci. U.S.A. 2000;97:13625–13630. doi: 10.1073/pnas.240309797. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Iwanaka T., Yamaza T., Sonoda S., Yoshimaru K., Matsuura T., Yamaza H., Ohga S., Oda Y., Taguchi T. A model study for the manufacture and validation of clinical-grade deciduous dental pulp stem cells for chronic liver fibrosis treatment. Stem Cell Res. Ther. 2020;11:134. doi: 10.1186/s13287-020-01630-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Karnieli O., Friedner O.M., Allickson J.G., Zhang N., Jung S., Fiorentini D., Abraham E., Eaker S.S., Yong T.K., Chan A., et al. A consensus introduction to serum replacements and serum-free media for cellular therapies. Cytotherapy. 2017;19:155–169. doi: 10.1016/j.jcyt.2016.11.011. [DOI] [PubMed] [Google Scholar]
  6. Ma L., Makino Y., Yamaza H., Akiyama K., Hoshino Y., Song G., Kukita T., Nonaka K., Shi S., Yamaza T. Cryopreserved dental pulp tissues of exfoliated deciduous teeth is a feasible stem cell resource for regenerative medicine. PLoS One. 2012;7:e51777. doi: 10.1371/journal.pone.0051777. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Ma L., Aijima R., Hoshino Y., Yamaza H., Tomoda E., Tanaka Y., Sonoda S., Song G., Zhao W., Nonaka K., et al. Transplantation of mesenchymal stem cells ameliorates secondary osteoporosis through interleukin-17-impaired functions of recipient bone marrow mesenchymal stem cells in MRL/lpr mice. Stem Cell Res. Ther. 2015;6:104. doi: 10.1186/s13287-015-0091-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Makino Y., Yamaza H., Akiyama K., Ma L., Hoshino Y., Nonaka K., Terada Y., Kukita T., Shi S., Yamaza T. Immune therapeutic potential of stem cells from human supernumerary teeth. J. Dent. Res. 2013;92:609–615. doi: 10.1177/0022034513490732. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Miura M., Gronthos S., Zhao M., Lu B., Fisher L.W., Robey P.G., Shi S. SHED: stem cells from human exfoliated deciduous teeth. Proc. Natl. Acad. Sci. U.S.A. 2003;100:5807–5812. doi: 10.1073/pnas.0937635100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Sonoda S., Tomoda E., Tanaka Y., Yamaza T. Properties and possibilities of human dental pulp-derived stem cells. Arch. Stem Cell Res. 2015;2:1012. doi: 10.13140/RG.2.1.2213.1684. [DOI] [Google Scholar]
  11. Sonoda S., Yamaza H., Ma L., Tanaka Y., Tomoda E., Aijima R., Nonaka K., Kukita T., Shi S., Nishimura F., Yamaza T. Interferon-gamma improves impaired dentinogenic and immunosuppressive functions of irreversible pulpitis-derived human dental pulp stem cells. Sci. Rep. 2016;6:19286. doi: 10.1038/srep19286. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Sonoda S., Mei Y.F., Atsuta I., Danjo A., Yamaza H., Hama S., Nishida K., Tang R., Kyumoto-Nakamura Y., Uehara N., et al. Exogenous nitric oxide stimulates the odontogenic differentiation of rat dental pulp stem cells. Sci. Rep. 2018;8:3419. doi: 10.1038/s41598-018-21183-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Sonoda S., Murata S., Nishida K., Kato H., Uehara N., Kyumoto Y.N., Yamaza H., Takahashi I., Kukita T., Yamaza T. Extracellular vesicles from deciduous pulp stem cells recover bone loss by regulating telomerase activity in an osteoporosis mouse model. Stem Cell Res. Ther. 2020;11:296. doi: 10.1186/s13287-020-01818-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Sonoda S., Murata S., Kato H., Zakaria F., Kyumoto-Nakamura Y., Uehara N., Yamaza H., Kukita T., Yamaza T. Targeting of deciduous tooth pulp stem cell-derived extracellular vesicles on telomerase-mediated stem cell niche and immune regulation in systemic lupus erythematosus. J. Immunol. 2021;206:3053–3063. doi: 10.4049/jimmunol.2001312. [DOI] [PubMed] [Google Scholar]
  15. Sonoda S., Yoshimaru K., Yamaza H., Yuniartha R., Matsuura T., Yamauchi-Tomoda E., Murata S., Nishida K., Oda Y., Ohga S., et al. Biliary atresia-specific deciduous pulp stem cells feature biliary deficiency. Stem Cell Res. Ther. 2021;12:582. doi: 10.1186/s13287-021-02652-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Sonoyama W., Liu Y., Fang D., Yamaza T., Seo B.M., Zhang C., Liu H., Gronthos S., Wang C.Y., Wang S., Shi S. Mesenchymal stem cell-mediated functional tooth regeneration in swine. PLoS One. 2006;1:e79. doi: 10.1371/journal.pone.0000079. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Taguchi T., Yanagi Y., Yoshimaru K., Zhang X.Y., Matsuura T., Nakayama K., Kobayashi E., Yamaza H., Nonaka K., Ohga S., Yamaza T. Regenerative medicine using stem cells from human exfoliated deciduous teeth (SHED): a promising new treatment in pediatric surgery. Surg. Today. 2019;49:316–322. doi: 10.1007/s00595-019-01783-z. [DOI] [PubMed] [Google Scholar]
  18. Takahashi Y., Yuniartha R., Yamaza T., Sonoda S., Yamaza H., Kirino K., Yoshimaru K., Matsuura T., Taguchi T. Therapeutic potential of spheroids of stem cells from human exfoliated deciduous teeth for chronic liver fibrosis and hemophilia A. Pediatr. Surg. Int. 2019;35:1379–1388. doi: 10.1007/s00383-019-04564-4. [DOI] [PubMed] [Google Scholar]
  19. Tanaka Y., Sonoda S., Yamaza H., Murata S., Nishida K., Hama S., Kyumoto-Nakamura Y., Uehara N., Nonaka K., Kukita T., Yamaza T. Suppression of AKT-mTOR signal pathway enhances osteogenic/dentinogenic capacity of stem cells from apical papilla. Stem Cell Res. Ther. 2018;9:334. doi: 10.1186/s13287-018-1077-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Tanaka Y., Sonoda S., Yamaza H., Murata S., Nishida K., Kyumoto-Nakamura Y., Uehara N., Nonaka K., Kukita T., Yamaza T. Acetylsalicylic acid treatment and suppressive regulation of AKT accelerate odontogenic differentiation of stem cells from the apical papilla. J. Endod. 2019;45:591–598.e6. doi: 10.1016/j.joen.2019.01.016. [DOI] [PubMed] [Google Scholar]
  21. Yamaza T., Kentaro A., Chen C., Liu Y., Shi Y., Gronthos S., Wang S., Shi S. Immunomodulatory properties of stem cells from human exfoliated deciduous teeth. Stem Cell Res. Ther. 2010;1:5. doi: 10.1186/scrt5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Yamaza T., Alatas F.S., Yuniartha R., Yamaza H., Fujiyoshi J.K., Yanagi Y., Yoshimaru K., Hayashida M., Matsuura T., Aijima R., et al. In vivo hepatogenic capacity and therapeutic potential of stem cells from human exfoliated deciduous teeth in liver fibrosis in mice. Stem Cell Res. Ther. 2015;6:171. doi: 10.1186/s13287-015-0154-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Yamaza H., Tomoda E., Sonoda S., Nonaka K., Kukita T., Yamaza T. Bilirubin reversibly affects cell death and odontogenic capacity in stem cells from human exfoliated deciduous teeth. Oral Dis. 2018;24:809–819. doi: 10.1111/odi.12827. [DOI] [PubMed] [Google Scholar]
  24. Yamaza H., Sonoda S., Nonaka K., Kukita T., Yamaza T. Pamidronate decreases bilirubin-impaired cell death and improves dentinogenic dysfunction of stem cells from human deciduous teeth. Stem Cell Res. Ther. 2018;9:303. doi: 10.1186/s13287-018-1042-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Yuniartha R., Yamaza T., Sonoda S., Yoshimaru K., Matsuura T., Yamaza H., Oda Y., Ohga S., Taguchi T. Cholangiogenic potential of human deciduous pulp stem cell-converted hepatocyte-like cells. Stem Cell Res. Ther. 2021;12:57. doi: 10.1186/s13287-020-02113-8. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

The data sets supporting this protocol, and used in Figures, have not been deposited in a public repository but are available from the corresponding author upon request.


Articles from STAR Protocols are provided here courtesy of Elsevier

RESOURCES